Multiple Endocrine Neoplasia Type 2 (MEN2)
Table of Contents
Overview
Multiple Endocrine Neoplasia Type 2 (MEN2) is a hereditary cancer syndrome characterized by the near-inevitable development of medullary thyroid carcinoma (MTC), a high lifetime risk of pheochromocytoma, and — in its most common subtype — a risk of primary hyperparathyroidism. The syndrome is inherited in an autosomal dominant pattern, meaning a single copy of a mutated gene is sufficient to cause disease, and each child of an affected parent has a 50% chance of inheriting the mutation. Penetrance for the defining tumor, MTC, approaches 100% over a lifetime, making MEN2 one of the most reliably penetrant hereditary cancer syndromes recognized in human genetics.
What sets MEN2 apart from most other cancer predisposition syndromes is the precision of its molecular basis. Virtually every case of MEN2 is caused by a germline gain-of-function mutation in the RET proto-oncogene — a single gene on chromosome 10q11.2 encoding a receptor tyrosine kinase expressed in neural crest-derived tissues. Unlike the loss-of-function tumor suppressor mutations that underlie most hereditary cancer syndromes (including MEN1), MEN2 mutations activate RET constitutively, driving uncontrolled proliferation in thyroid C-cells, adrenal chromaffin cells, and parathyroid chief cells. The specific codon mutated in RET predicts both the clinical subtype and the aggressiveness of the disease — a genotype-phenotype correlation so reliable that it now directly guides surgical timing, sometimes dictating prophylactic thyroidectomy in the first months of life.
MEN2 is subdivided into three clinical syndromes: MEN2A (the most common, accounting for roughly 75% of cases), MEN2B (the rarest and most aggressive, approximately 5%), and Familial Medullary Thyroid Carcinoma (FMTC, about 20%). Understanding which subtype a patient has — and which specific codon carries the mutation — shapes every clinical decision from surveillance intervals to the urgency of prophylactic surgery.
Genetics and the RET Oncogene
The RET proto-oncogene (Rearranged during Transfection) encodes a receptor tyrosine kinase that plays a critical role in the development of neural crest-derived cells and the urogenital system. The protein consists of an extracellular ligand-binding domain, a single transmembrane segment, and an intracellular kinase domain. Under normal circumstances, RET is activated only when its ligands — members of the glial cell line-derived neurotrophic factor (GDNF) family — bind in conjunction with co-receptors called GDNF family receptor-alpha (GFRα) proteins. This ligand-induced dimerization triggers autophosphorylation of the intracellular kinase domain and initiates downstream signaling through the RAS/MAPK, PI3K/AKT, and PLC-gamma pathways, promoting cell survival, proliferation, and differentiation.
MEN2-causing mutations convert RET from a proto-oncogene into an oncogene by producing constitutive, ligand-independent kinase activity. This is a gain-of-function mechanism — fundamentally different from MEN1, in which loss of the tumor suppressor menin disrupts a brake on cell growth. MEN2 mutations are germline (present in every cell of the body) and virtually all are missense mutations — single nucleotide substitutions that change one amino acid in the RET protein.
The specific codon mutated carries profound clinical implications. Mutations in the extracellular cysteine-rich domain (exons 10 and 11, codons 609, 611, 618, 620, and 634) typically cause receptor dimerization without ligand, creating a constitutively active receptor. Mutations in the intracellular kinase domain (exons 13–16, codons 768, 790, 791, 804, 891, and the critical 918) activate the kinase domain directly. Codon 634 mutations (most commonly Cys→Arg or Cys→Gly) are the most frequent MEN2A mutations and carry the highest risk within the MEN2A spectrum. Codon 918 (Met→Thr, exon 16) is essentially pathognomonic for MEN2B and represents the most activating — and most dangerous — known RET mutation.
Risk stratification based on RET codon has been formalized in the 2015 revised guidelines of the American Thyroid Association (ATA), which classify mutations into three risk categories — highest risk (ATA-HST), high risk (ATA-H) and moderate risk (ATA-MOD) — that guide the timing of prophylactic thyroidectomy:
- Highest risk (ATA-HST): Codon 918 (M918T, exon 16) — MEN2B phenotype; the guideline recommends thyroidectomy in the first year of life, perhaps even in the first months of life.
- High risk (ATA-H): Codon 634 (exon 11, all variants) — classic MEN2A — and codon 883 (A883F, exon 15), which is found in fewer than 5% of people with MEN2B; the guideline recommends thyroidectomy at or before age 5 years, earlier if serum calcitonin is raised.
- Moderate risk (ATA-MOD): All other codons, including 609, 611, 618, 620 (exon 10), 630 (exon 11), and 768, 790, 791, 804, 891 (kinase domain) — the guideline places thyroidectomy in childhood or young adulthood, timed mainly by serum calcitonin, with physical examination, neck ultrasound and calcitonin measurement beginning around age 5.
Genetic testing for RET mutations has become the cornerstone of MEN2 management. When a carrier is identified, cascade testing is offered to all first-degree relatives. A negative RET test in a family member of a known mutation carrier effectively rules out MEN2 and eliminates the need for lifelong biochemical surveillance.
MEN2 Subtypes
MEN2A is the most common subtype, comprising approximately 75% of all MEN2 cases. Its defining features are medullary thyroid carcinoma (MTC), pheochromocytoma, and primary hyperparathyroidism (HPT). MTC occurs in nearly 100% of MEN2A patients over a lifetime. Pheochromocytoma develops in roughly 50%, and primary HPT in 20–30%. The classic MEN2A codon 634 mutation carries the highest combined risk for all three components. A rare variant of MEN2A — called MEN2A with cutaneous lichen amyloidosis — features pruritic plaques over the upper back in addition to the classic triad; it is associated with specific codon 634 mutations. Another variant, MEN2A with Hirschsprung disease, is associated with mutations in codons 609, 611, 618, and 620 and results from loss-of-function effects on RET signaling in enteric neural crest cells.
MEN2B accounts for only about 5% of MEN2 cases but is the most aggressive subtype. The codon 918 mutation responsible for MEN2B produces a dramatically more activated kinase than MEN2A mutations. MTC in MEN2B presents at an earlier age than any other subtype — sometimes in infancy — and metastasizes earlier and more aggressively. In addition to MTC and pheochromocytoma (50% lifetime risk), MEN2B produces a distinctive phenotype not seen in MEN2A: marfanoid body habitus (tall stature, long limbs, pectus excavatum, high arched palate, scoliosis) without the cardiovascular and ocular complications of true Marfan syndrome; mucosal neuromas on the lips, tongue, and conjunctivae that are visible as bumpy, nodular thickenings; and intestinal ganglioneuromatosis with diffuse ganglioneuromas throughout the gastrointestinal tract causing constipation, megacolon, and feeding difficulties in infancy. MEN2B does not include hyperparathyroidism. According to the 2015 ATA guideline, approximately 75% of MEN2B cases are sporadic, caused by a new (de novo) RET mutation in a child of unaffected parents, while 25% occur in families already affected by MEN2B.
Familial Medullary Thyroid Carcinoma (FMTC) is defined as two or more family members with MTC but without pheochromocytoma or hyperparathyroidism across multiple generations of documented follow-up. FMTC is now considered a variant of MEN2A rather than a distinct syndrome, because some families initially classified as FMTC later develop pheochromocytoma as surveillance continues. FMTC-associated mutations are generally in the moderate-risk tier (exon 10 codons and kinase domain codons), and the MTC tends to be less aggressive than in classic MEN2A or MEN2B. Management remains the same: prophylactic thyroidectomy guided by codon-specific risk tier.
Medullary Thyroid Carcinoma
Medullary thyroid carcinoma arises from the parafollicular C-cells of the thyroid gland — neural crest-derived cells that produce and secrete calcitonin, a calcium-lowering hormone distinct from the T3 and T4 produced by the surrounding follicular epithelium. Because C-cells do not take up iodine, MTC does not respond to radioactive iodine therapy, a critical distinction from papillary and follicular thyroid cancers that accounts for much of MTC's distinct management pathway.
In MEN2, MTC is typically bilateral and multifocal at presentation, reflecting the field effect of the germline RET mutation on all C-cells throughout both thyroid lobes. This contrasts with sporadic MTC (which accounts for about 75% of all MTC cases), which is usually unifocal and unilateral. Hereditary MTC also presents at a younger age and has a more favorable prognosis when caught preclinically through genetic screening — a key argument for prophylactic thyroidectomy in mutation carriers before MTC develops.
The primary tumor marker for MTC is calcitonin, produced by C-cells constitutively and in excess by MTC cells. Basal serum calcitonin levels correlate with tumor burden and are used for diagnosis, surgical planning, and post-operative surveillance. Calcitonin levels above 200 pg/mL are associated with a high likelihood of lateral neck lymph node metastases, guiding the extent of surgical dissection. Carcinoembryonic antigen (CEA) is a second tumor marker produced by MTC; rising CEA with stable calcitonin (the so-called calcitonin-CEA discordance) may signal tumor dedifferentiation and warrants attention. In some countries, pentagastrin-stimulated calcitonin testing is used to detect early C-cell hyperplasia before frank malignancy develops, though this test is not available in the United States.
Highly elevated calcitonin can directly cause profuse watery diarrhea through activation of intestinal secretion — a symptom that alerts clinicians to a high tumor burden even before imaging reveals metastases. Other systemic manifestations of advanced MTC include flushing (from calcitonin and accompanying peptide secretion) and, rarely, Cushing syndrome if the tumor ectopically secretes adrenocorticotropic hormone (ACTH).
Surgery is the only curative treatment for MTC. The operation is total thyroidectomy combined with central neck dissection (bilateral levels VI and VII), regardless of whether lymph nodes appear involved on imaging, because microscopic central node disease is common and calcitonin normalization rates are substantially higher when the central compartment is cleared. If pre-operative calcitonin exceeds 200 pg/mL, or if imaging identifies lateral neck adenopathy, ipsilateral (or bilateral if indicated) lateral neck dissection of levels II–V is added. Survival is strongly linked to whether calcitonin normalizes after surgery — normalization indicates biochemical cure, while persistently detectable calcitonin confirms residual or metastatic disease.
For patients with metastatic or progressive MTC not amenable to surgery, targeted therapies directed at RET have transformed the landscape. The highly selective RET inhibitors selpercatinib and pralsetinib produced response rates of roughly 60–73% in patients with RET-mutant MTC in their early trials, and selpercatinib outperformed the older drugs in a phase 3 trial (see Treatment and Surveillance). In the United States, the pralsetinib indication for MTC was later withdrawn after the required confirmatory phase 3 trial could not be completed. Earlier multikinase inhibitors — vandetanib (RET/VEGFR/EGFR inhibitor) and cabozantinib (RET/MET/VEGFR2 inhibitor) — demonstrated progression-free survival benefit and remain options, particularly when selective RET inhibitors are unavailable, though their broader off-target activity produces more adverse effects including hypertension, diarrhea, hand-foot syndrome, and QT prolongation.
Pheochromocytoma in MEN2
Pheochromocytoma — a catecholamine-secreting tumor of the adrenal medullary chromaffin cells — develops in approximately 50% of individuals with MEN2 over a lifetime. Among those who develop pheochromocytoma, about half have bilateral disease. This bilateral predisposition reflects the same field effect of the germline RET mutation that causes bilateral MTC: the mutation is present in every chromaffin cell, and although only some progress to frank tumor, the risk is distributed across both adrenal glands.
An important and potentially life-saving observation: pheochromocytomas in MEN2 are almost always benign — malignant pheochromocytoma occurs in fewer than 5% of MEN2 cases, compared to approximately 10–17% in sporadic pheochromocytoma. However, benign does not mean safe. The catecholamine excess produced by pheochromocytoma — typically epinephrine and norepinephrine, with variable dopamine — can cause hypertensive crises, cardiac arrhythmias, and sudden death if the tumor is unrecognized and patients undergo anesthesia or surgery without appropriate preparation.
This is the most critical safety principle in MEN2 management: pheochromocytoma is screened for and excluded before any thyroid or parathyroid surgery. An undiagnosed pheochromocytoma subjected to the catecholamine surges of induction, manipulation, or pain during surgery can precipitate a fatal hypertensive crisis. The preferred biochemical screening tests are plasma free metanephrines or 24-hour urine fractionated metanephrines — both significantly more sensitive than urine catecholamines alone. Imaging with computed tomography (CT) or magnetic resonance imaging (MRI) of the adrenal glands is performed once biochemistry is positive.
When pheochromocytoma is confirmed, surgical resection is performed before thyroidectomy, even if MTC has already been diagnosed. Pre-operative alpha-adrenergic blockade is standard practice: phenoxybenzamine (a non-competitive, long-acting alpha blocker) or doxazosin (selective alpha-1 blocker) is administered for 10 to 14 days before surgery to restore normal vascular tone and prevent intraoperative hypertensive crisis. Only after adequate alpha blockade is established — confirmed by orthostatic hypotension and normalization of blood pressure — is beta-adrenergic blockade (such as propranolol) added to control reflex tachycardia. Giving a beta-blocker before alpha-blockade is established can cause paradoxical severe hypertension, because alpha-adrenergic stimulation is then left unopposed.
The surgical approach is laparoscopic adrenalectomy. In patients with bilateral pheochromocytoma, cortical-sparing (partial) adrenalectomy is strongly preferred over bilateral total adrenalectomy, because preservation of even a rim of functional adrenal cortex avoids lifelong glucocorticoid and mineralocorticoid replacement therapy and the associated risk of adrenal crisis. Bilateral total adrenalectomy leaves patients entirely dependent on exogenous steroids for life — a significant quality-of-life burden and a mortal risk if doses are missed during intercurrent illness.
An international study of 1210 people with MEN2 from 30 centers (563 with pheochromocytoma) compared the two operations. Pheochromocytoma came back in 3% of glands (4 of 153) after adrenal-sparing surgery, 6 to 13 years later, and in 2% of glands (11 of 717) after full adrenalectomy, a difference that was not statistically significant. Of the 339 people operated on for pheochromocytoma in both adrenals, 86% became steroid-dependent or developed adrenal insufficiency; but 57% (47 of 82) of those who had adrenal-sparing surgery did not become steroid-dependent. The authors concluded that adrenal-sparing surgery, done in experienced centers, should be the surgical approach of choice.
Hyperparathyroidism and Other Features
Primary hyperparathyroidism (HPT) develops in approximately 20–30% of patients with MEN2A. Unlike the multiglandular hyperplasia that characterizes HPT in MEN1 — where all four glands are typically affected — HPT in MEN2A usually presents as a single-gland adenoma with mild, often asymptomatic hypercalcemia. This difference in glandular involvement between MEN1 and MEN2A HPT has direct surgical implications: MEN2A patients who require parathyroidectomy may be treated with targeted resection of the single enlarged gland rather than the subtotal or total parathyroidectomy with autotransplantation generally required for MEN1.
Because HPT in MEN2A tends to be mild and asymptomatic, it is frequently diagnosed only when serum calcium is routinely checked during MEN2A surveillance. Symptomatic hypercalcemia — nephrolithiasis, bone disease, neuromuscular symptoms — is less common in MEN2A HPT than in sporadic or MEN1-associated HPT. Management follows the same general principles as sporadic PHPT: asymptomatic patients with modest hypercalcemia and preserved bone density may be followed, while those meeting surgical indications (calcium more than 1 mg/dL above the upper limit of normal, symptomatic disease, osteoporosis, or age under 50) undergo parathyroid surgery. When parathyroid surgery is indicated and thyroidectomy is being performed concurrently, the parathyroid glands can be addressed at the same operation.
MEN2B produces distinctive extra-endocrine features not seen in MEN2A or FMTC. The marfanoid habitus — tall stature, dolichostenomelia (disproportionately long limbs and digits), pectus excavatum, high arched palate, scoliosis, and joint laxity — mimics Marfan syndrome but lacks its defining cardiovascular (aortic root dilation) and ocular (ectopia lentis) manifestations. This distinction matters because Marfan syndrome requires ongoing cardiac surveillance and activity restrictions that MEN2B does not.
Mucosal neuromas are pathognomonic for MEN2B and represent one of its earliest and most diagnostically valuable features. These small, pearly nodular growths appear on the anterior third of the tongue, lips, and conjunctivae — often visible as a distinctly bumpy, nodular appearance to the lips and anterior tongue. They may appear in infancy, frequently before MTC is detectable. In a child or adolescent with bumpy lips and tongue and no other explanation, MEN2B is the leading diagnosis to exclude, and RET mutation testing (specifically for the codon 918 mutation) is the test that settles it.
Intestinal ganglioneuromatosis — diffuse involvement of the enteric nervous system by ganglioneuromas — produces gastrointestinal dysmotility in MEN2B patients from infancy. Constipation, megacolon, distension, and feeding difficulties are common presenting symptoms in affected neonates and infants. The ganglioneuromas are diffusely distributed throughout the gastrointestinal tract from esophagus to rectum, unlike the localized hirschsprung-type aganglionosis caused by loss-of-function RET mutations.
Diagnosis and Screening
The diagnostic evaluation of MEN2 centers on three pillars: genetic testing for germline RET mutations, biochemical screening for each component tumor, and imaging when biochemistry is positive. The identification of a RET mutation in a proband leads to cascade genetic testing of all first-degree relatives — parents, siblings, and children — because each carries a 50% prior probability of having inherited the mutation.
Genetic testing for MEN2 targets the known hotspot codons in RET. Sequencing of the entire coding region and splice sites is now standard, as next-generation sequencing panels have made comprehensive testing accessible and affordable. Virtually all MEN2 cases (greater than 98%) have an identifiable germline RET mutation, making a negative result in a family member of a known mutation carrier essentially reassuring. Rare cases without an identifiable mutation may reflect atypical mutations outside the standard sequencing targets, which specialized hereditary cancer centers can look for.
Biochemical screening for each component tumor is performed at defined intervals in confirmed mutation carriers:
- MTC: Basal serum calcitonin annually. A rising calcitonin in a patient who has undergone prophylactic thyroidectomy suggests residual C-cell tissue or persistent disease. CEA is measured concurrently; calcitonin doubling time and CEA doubling time are the strongest prognostic markers for survival in persistent or recurrent MTC.
- Pheochromocytoma: Plasma free metanephrines or 24-hour urine fractionated metanephrines annually; the 2015 ATA guideline places the start by age 11 years in the ATA-HST and ATA-H categories and by age 16 years in the ATA-MOD category (or from the time of genetic diagnosis in older patients). The test is repeated before any planned surgery regardless of the result of the prior year's screen.
- HPT: Serum calcium (with or without intact parathyroid hormone, PTH) annually in MEN2A/FMTC mutation carriers, beginning at age 11 years in the ATA-H category and at age 16 years in the ATA-MOD category, according to the 2015 ATA guideline.
Imaging is performed when biochemistry is abnormal rather than as primary surveillance. Neck ultrasound is the first-line imaging tool for MTC evaluation and surgical planning. Adrenal computed tomography or magnetic resonance imaging is performed when plasma or urine metanephrines are elevated. Cross-sectional imaging of the chest, abdomen, and pelvis is indicated when calcitonin levels suggest distant metastatic disease. Functional imaging with FDG-PET or DOTATATE-PET may localize recurrent or metastatic MTC in patients with biochemical evidence of persistent disease but negative conventional imaging.
In a patient presenting with apparently sporadic MTC (no family history), RET germline mutation testing is still performed, because, according to the 2015 ATA guideline, 1%–7% of patients with presumed sporadic MTC actually have hereditary disease with a de novo or unrecognized family mutation. Additionally, somatic RET mutations (acquired, not germline) are present in approximately 40–60% of truly sporadic MTC cases and have treatment implications, since RET-mutant sporadic MTC responds well to selpercatinib and pralsetinib.
Treatment and Surveillance
Treatment in MEN2 is guided by the specific subtype, the codon mutated, and the component tumors present. The overarching principle is that early intervention — ideally prophylactic thyroidectomy before MTC develops — produces dramatically better outcomes than waiting for symptomatic disease.
Prophylactic thyroidectomy is the most effective intervention in MEN2. The timing is dictated by the ATA risk tier:
- Codon 918 (MEN2B, ATA-HST): thyroidectomy in the first year of life, perhaps even in the first months of life, once the diagnosis is confirmed genetically.
- Codon 634 and codon 883 (ATA-H): thyroidectomy at or before age 5 years, earlier if serum calcitonin is raised.
- Moderate-risk codons (ATA-MOD): examination, neck ultrasound and calcitonin from around age 5, with thyroidectomy in childhood or young adulthood timed mainly by a rising serum calcitonin; some parents choose thyroidectomy around age 5 rather than years of check-ups.
Total thyroidectomy is the required extent of resection — hemithyroidectomy is not adequate because MTC in MEN2 is bilateral and multifocal. Central neck dissection is added if basal calcitonin is elevated pre-operatively, suggesting C-cell hyperplasia beyond the gland itself. Post-operative thyroid hormone replacement with levothyroxine is lifelong; unlike differentiated thyroid cancer, thyroid-stimulating hormone (TSH) suppression is not required after MTC surgery because C-cells are not thyroid-stimulating hormone-responsive.
Management of pheochromocytoma follows the sequence described above: alpha blockade first, then beta blockade, then laparoscopic adrenalectomy, with cortical-sparing technique for bilateral disease. Annual surveillance with plasma metanephrines continues after adrenalectomy because the contralateral gland (if not yet resected) or remnant adrenal tissue may develop new pheochromocytoma over time.
Management of HPT in MEN2A is typically parathyroidectomy of the enlarged gland(s) when surgical criteria are met. Because MEN2A HPT is usually single-gland, focused parathyroidectomy with intraoperative parathyroid hormone monitoring is appropriate, in contrast to the more extensive resections required for MEN1 HPT. When concurrent thyroidectomy is planned, careful preservation of non-adenomatous parathyroid glands — or autotransplantation into the sternocleidomastoid muscle — prevents post-operative hypoparathyroidism.
Systemic therapy for metastatic MTC has been transformed by selective RET inhibitors. In the LIBRETTO-001 trial, selpercatinib (LOXO-292) produced a response in 69% of 55 patients previously treated with vandetanib or cabozantinib (82% free of progression at 1 year) and in 73% of 88 untreated patients (92% free of progression at 1 year); the most common severe side effects were high blood pressure (21%) and raised liver enzymes (9–11%), and 2% of all treated patients stopped the drug because of side effects. Pralsetinib showed response rates of 71% (untreated) and 60% (previously treated) in the ARROW trial; its U.S. indication for MTC was later withdrawn. A 2026 review describes selective RET inhibitors as the preferred first-line therapies for RET-mutant MTC. For patients who cannot access selective RET inhibitors, the multikinase inhibitors vandetanib and cabozantinib extend progression-free survival (each demonstrating benefit in phase III randomized trials) and remain approved options. External beam radiation therapy has a limited role — primarily for symptomatic bony metastases or when local control of unresectable cervical disease is needed — because MTC does not respond to radioiodine.
Head-to-head phase 3 results. The LIBRETTO-531 trial randomly assigned 291 people with progressive advanced RET-mutant MTC who had never taken a kinase inhibitor to selpercatinib or to the doctor's choice of cabozantinib or vandetanib. At a median follow-up of 12 months, median progression-free survival was not reached with selpercatinib versus 16.8 months with the older drugs (hazard ratio for progression or death 0.28); 86.8% versus 65.7% were free of progression at 12 months, and 69.4% versus 38.8% had a tumor response. Side effects led to stopping treatment in 4.7% versus 26.8%. In a follow-up analysis of weekly patient questionnaires (242 people), those on selpercatinib spent 8% of their treatment time with a "high" side-effect burden, compared with 24% on cabozantinib or vandetanib, with less time with severe diarrhea (5% vs 38%) and fatigue (6% vs 21%).
Long-term LIBRETTO-001 results. In the 2024 update covering 324 people with RET-mutant MTC, 82.5% of those never given cabozantinib or vandetanib had a tumor response. Median progression-free survival was 41.4 months in previously treated patients and had not been reached in untreated patients after a median of 42.4 months of follow-up; 75.2% of the untreated group were free of progression at 3 years.
Long-term surveillance for MEN2 patients who have undergone prophylactic thyroidectomy includes annual basal calcitonin and CEA (with imaging triggered by rising levels), annual plasma metanephrines (for pheochromocytoma surveillance), and annual serum calcium and parathyroid hormone for MEN2A/FMTC patients. Calcitonin doubling time under 6 months correlates with poor prognosis and is one of the triggers for considering systemic therapy. In a study cited by the 2015 ATA guideline (65 patients followed after total thyroidectomy and lymph node dissection), 5- and 10-year survival was 25% and 8% when the calcitonin doubling time was under 6 months, compared with 92% and 37% when it was 6–24 months; all patients with doubling times over 24 months were alive at the end of the study.
Key Research Papers
- Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993;363(6428):458–460. — PubMed PMID: 8099202
- Hofstra RM, Landsvater RM, Ceccherini I, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994;367(6461):375–376. — PubMed PMID: 7906866
- Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 1996;276(19):1575–1579. — PubMed PMID: 8918855
- Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015;25(6):567–610. — PubMed PMID: 25810047
- Elisei R, Cosci B, Romei C, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 2008;93(3):682–687. — PubMed PMID: 18073307
- Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012;30(2):134–141. — PubMed PMID: 22025146
- Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013;31(29):3639–3646. — PubMed PMID: 24002501
- Wirth LJ, Sherman E, Robinson B, et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med 2020;383(9):825–835. — PubMed PMID: 32846061
- Subbiah V, Hu MI, Wirth LJ, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol 2021;9(8):491–501. — PubMed PMID: 34118198
- Castinetti F, Qi XP, Walz MK, et al. Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study. Lancet Oncol 2014;15(6):648–655. — PubMed PMID: 24745698
- Hadoux J, Elisei R, Brose MS, et al. Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer. N Engl J Med 2023;389(20):1851–1861. — PubMed PMID: 37870969
- Wirth LJ, Brose MS, Subbiah V, et al. Durability of response with selpercatinib in patients with RET-activated thyroid cancer: long-term safety and efficacy from LIBRETTO-001. J Clin Oncol 2024;42(27):3187–3195. — PubMed PMID: 39094065
- Elisei R, Wirth LJ, Capdevila J, et al. Patient-reported tolerability of selpercatinib compared to cabozantinib/vandetanib: a secondary analysis of the LIBRETTO-531 randomized-controlled trial in RET-mutant medullary thyroid cancer. Thyroid 2025;35(10):1162–1172. — PubMed PMID: 40828665
- Arain HA, Izhar A, Caretti R, Chen H, Vodopivec DM. Targeted therapies in the management of advanced medullary thyroid cancer. Oncologist 2026;31(9):oyag300. — PubMed PMID: 42525389